ASTRO Issues Its First Clinical Guideline on Radiation Therapy for Bladder Cancer
For appropriately selected patients with muscle-invasive bladder cancer, bladder preservation can be a curative treatment option, according to a new clinical guideline from the American Society for Radiation Oncology (ASTRO). The recommendations support trimodal therapy (maximal transurethral resection of bladder tumor followed by chemoradiation for bladder preservation) as an alternative to radical cystectomy and provide guidance on the use of radiation therapy after surgery and for patients with metastatic or symptomatic disease. The guideline, ASTRO’s first focused specifically on radiation therapy across bladder cancer care, was published by Ballas et al in Practical Radiation Oncology.
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
A lower-cost chemoimmunotherapy approach including triple oral metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from India who reported results with the novel regimen at the 2026 ASCO Annual Meeting.1
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
In the large, platform-based, independent validation study CATALINA, published by Dixon-Douglas et al in The Lancet Oncology, two artificial intelligence (AI)-derived computational tumor-infiltrating lymphocyte (cTIL) models, which were deployed without retraining or modification, provided statistically significant prognostic information and improved risk discrimination beyond clinicopathologic variables alone in patients with early-stage triple-negative breast cancer.
Alcohol-Attributable Cancer Deaths More Than Double in the United States
Cancer mortality associated with alcohol use has risen in the United States, disproportionately affecting males and adults aged at least 55 years, according to a population-based observational trend analysis published by Jani et al in The Lancet Regional Health – Americas.
AI’s Evolving Role in Clinical Care Enterprise-Wide
Artificial intelligence could reshape health care by reducing administrative work, helping physicians identify and manage disease, and extending care beyond traditional clinical settings—potentially allowing caregivers to focus more on patient care and human interaction, according to Cleveland Clinic executive leaders.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
From Results to Action: Leveraging Multidisciplinary Teams to Optimize NSCLC CareMore Top Stories
Surviving Cancer Put Me On a Career Path in Cancer Research
I was just 24 and in seemingly perfect health when I began experiencing unexplained abdominal pain so excruciating, even daily doses of pain medication failed to provide relief. I was a senior in college and had enrolled in a summer internship program at the University of California, Davis, when my ...
BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows
Researchers have identified varying clinicopathologic characteristics and outcomes between patients with non–small cell lung cancer (NSCLC) and class II and III BRAF mutations, according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World...
‘Save Research’ Campaign Champions Federal Funding
ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline. “The People Behind the Progress,” an ASCO social media series, features members sharing how federal cancer research has...
20th Annual Award for Leadership in Personalized Medicine
The Personalized Medicine Coalition (PMC), a nonprofit organization dedicated to advancing personalized medicine, recently announced that physician-scientist Norman E. “Ned” Sharpless, MD, has been selected as the recipient of the 20th Annual Award for Leadership in Personalized Medicine,...
AACR Releases Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released the 16th edition of its annual Cancer Progress Report. This comprehensive report provides current data on cancer incidence, mortality, and survivorship. It also outlines how basic, translational, and clinical cancer research and...
Envafolimab Regimen Improves Pathologic Complete Response in MSS Locally Advanced Rectal Cancer
Adding the subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX (capecitabine and oxaliplatin) improved pathologic complete response (pCR) without a clear safety or surgical feasibility penalty in patients with microsatellite-stable (MSS) locally advanced rectal cancer,...
KEYNOTE-826: Long-Term Outcomes With Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
Five-year follow-up from the phase III KEYNOTE-826 trial suggests a durable benefit with first-line pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, in patients with recurrent or metastatic cervical cancer, according to Hasegawa et al in JAMA Oncology. At the first...
